Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Rating of “Moderate Buy” by Brokerages

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has received an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $37.70.

Several research analysts have issued reports on the stock. Guggenheim increased their target price on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, October 8th. Wall Street Zen raised shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 27th. Finally, Wells Fargo & Company upped their target price on Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th.

Centessa Pharmaceuticals Trading Down 1.5%

CNTA opened at $22.68 on Wednesday. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The stock’s fifty day moving average is $26.16 and its two-hundred day moving average is $21.26. The company has a market capitalization of $3.05 billion, a P/E ratio of -12.39 and a beta of 1.56. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $30.58.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). Analysts forecast that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Buying and Selling

In related news, CTO Tia L. Bush sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the sale, the chief technology officer owned 121,503 shares of the company’s stock, valued at $3,159,078. This trade represents a 24.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mario Alberto Accardi sold 10,000 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the completion of the transaction, the insider owned 178,801 shares of the company’s stock, valued at $5,364,030. This represents a 5.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 64,000 shares of company stock worth $1,674,460 in the last three months. 7.09% of the stock is owned by insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of CNTA. China Universal Asset Management Co. Ltd. grew its holdings in Centessa Pharmaceuticals by 4.8% in the second quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock worth $252,000 after purchasing an additional 870 shares during the last quarter. HighMark Wealth Management LLC boosted its position in shares of Centessa Pharmaceuticals by 0.6% in the 2nd quarter. HighMark Wealth Management LLC now owns 237,285 shares of the company’s stock worth $3,118,000 after purchasing an additional 1,500 shares in the last quarter. HighVista Strategies LLC grew its stake in Centessa Pharmaceuticals by 4.3% during the 2nd quarter. HighVista Strategies LLC now owns 40,684 shares of the company’s stock worth $535,000 after buying an additional 1,664 shares during the last quarter. Osterweis Capital Management Inc. acquired a new position in Centessa Pharmaceuticals during the 1st quarter valued at about $47,000. Finally, Legal & General Group Plc increased its position in Centessa Pharmaceuticals by 3.5% during the 3rd quarter. Legal & General Group Plc now owns 101,693 shares of the company’s stock valued at $2,464,000 after buying an additional 3,437 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.